Premium
Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Author(s) -
Richez Valentine,
Gruchet Cecile,
Guidez Stephanie,
Fouquet Guillemette,
Azais Isabelle,
Durand Geraldine,
Javaugue Vincent,
Brigaud Antoine,
Plasse Florent,
Diolez Jéremie,
Machet Antoine,
Moya Niels,
Gardeney Helene,
Franques Paul,
Bobin Arthur,
Levy Anthony,
Sabirou Florence,
Bonnin Anthony,
Dieval Celine,
Primault Sylvain,
Barrier Jocelyn,
Fleck Emmanuel,
Bouyier Sabrina,
Daras Claire,
Princet Isabelle,
Bauwens Delphine,
Legros Laurence,
Fuzibet JeanGabriel,
Gil Angela,
Bridoux Frank,
AvetLoiseau Hervé,
Leleu Xavier
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25327
Subject(s) - carfilzomib , lenalidomide , dexamethasone , medicine , multiple myeloma , regimen , adverse effect , refractory (planetary science) , bortezomib , proteasome inhibitor , oncology , pharmacology , gastroenterology , biology , astrobiology